Compare LSTA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSTA | COCH |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | LSTA | COCH |
|---|---|---|
| Price | $1.87 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.50 | $9.50 |
| AVG Volume (30 Days) | 29.5K | ★ 185.9K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000.00 | $208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $0.64 |
| 52 Week High | $4.20 | $1.91 |
| Indicator | LSTA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 43.75 |
| Support Level | $1.84 | $0.66 |
| Resistance Level | $2.02 | $0.75 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.61 | 21.05 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.